Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02279693

Acronym

PROSTRACK

Enrollment

Registered

2014-10-31

Start date

2014-12-22

Completion date

2019-08-06

Last updated

2024-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Raypilot dosimetry, CBCT (cone beam computed tomography)

Brief summary

This study evaluates the dose received by the prostate with in vivo dosimetry when delivering image guided radiation therapy (IGRT) associated with intensity modulated radiation therapy (IMRT) for patients with localized prostate cancer using two repositioning techniques: fiduciary markers or soft tissues.

Detailed description

10 participants will receive a cone beam computed tomography (CBCT) repositioning, while the other 10 will receive a kV imaging of fiducial marker repositioning. The principal objective is to evaluate and compare the dose received by the prostate using two repositioning techniques.

Interventions

OTHERCBCT

10 participants will receive a cone beam computed tomography (CBCT) repositioning

OTHERfiducial marker (kV imaging)

10 participants will receive a kV imaging of fiducial marker repositioning.

RADIATIONIGRT Associated With IMRT

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* male \> 18 years * carcinoma of the prostate histologically confirmed * OMS 0-1 * localized stage * favorable, intermediate and unfavorable groups according to NCCN or D'Amico classification * patients must have signed a written informed consent form * patients must be affiliated to a Social Health Insurance.

Exclusion criteria

* metastasis * indication for pelvic radiation * anticoagulant therapy * lateral or bilateral hip replacement * patient receiving an adult protective services * Patient unable to comply with the required medical follow-up for geographic, social or psychological reasons

Design outcomes

Primary

Measure	Time frame
dosimetry (measurement of the absorbed dose, delivered to prostate, by ionizing radiation)	8 weeks

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026